Palisade Bio (PALI) Competitors $2.15 -0.25 (-10.42%) (As of 10:08 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends PALI vs. TLPH, WENA, IMNN, CDIO, NLSP, TSBX, JAGX, ENSC, ATHE, and IPAShould you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Talphera (TLPH), ANEW Medical (WENA), Imunon (IMNN), Cardio Diagnostics (CDIO), NLS Pharmaceutics (NLSP), Turnstone Biologics (TSBX), Jaguar Health (JAGX), Ensysce Biosciences (ENSC), Alterity Therapeutics (ATHE), and ImmunoPrecise Antibodies (IPA). These companies are all part of the "pharmaceutical products" industry. Palisade Bio vs. Talphera ANEW Medical Imunon Cardio Diagnostics NLS Pharmaceutics Turnstone Biologics Jaguar Health Ensysce Biosciences Alterity Therapeutics ImmunoPrecise Antibodies Talphera (NASDAQ:TLPH) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations. Is TLPH or PALI more profitable? Talphera's return on equity of -118.46% beat Palisade Bio's return on equity.Company Net Margins Return on Equity Return on Assets TalpheraN/A -118.46% -65.82% Palisade Bio N/A -148.51%-115.16% Do insiders and institutionals believe in TLPH or PALI? 37.7% of Talphera shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 3.2% of Talphera shares are held by insiders. Comparatively, 3.3% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to TLPH or PALI? In the previous week, Palisade Bio had 3 more articles in the media than Talphera. MarketBeat recorded 5 mentions for Palisade Bio and 2 mentions for Talphera. Talphera's average media sentiment score of 1.89 beat Palisade Bio's score of 0.75 indicating that Talphera is being referred to more favorably in the media. Company Overall Sentiment Talphera Very Positive Palisade Bio Positive Does the MarketBeat Community believe in TLPH or PALI? Palisade Bio received 4 more outperform votes than Talphera when rated by MarketBeat users. However, 100.00% of users gave Talphera an outperform vote while only 50.00% of users gave Palisade Bio an outperform vote. CompanyUnderperformOutperformTalpheraOutperform Votes6100.00% Underperform VotesNo VotesPalisade BioOutperform Votes1050.00% Underperform Votes1050.00% Do analysts recommend TLPH or PALI? Talphera currently has a consensus target price of $4.50, suggesting a potential upside of 492.18%. Palisade Bio has a consensus target price of $23.00, suggesting a potential upside of 969.77%. Given Palisade Bio's higher possible upside, analysts plainly believe Palisade Bio is more favorable than Talphera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Palisade Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, TLPH or PALI? Palisade Bio has lower revenue, but higher earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTalphera$650K19.91-$18.40M-$0.69-1.10Palisade Bio$250K11.44-$12.30M-$13.98-0.15 Which has more risk & volatility, TLPH or PALI? Talphera has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. SummaryTalphera beats Palisade Bio on 10 of the 18 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Palisade Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PALI vs. The Competition Export to ExcelMetricPalisade BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.86M$3.09B$5.20B$8.97BDividend YieldN/A1.84%5.23%4.04%P/E Ratio-0.1515.2685.7113.39Price / Sales11.44315.091,469.4286.49Price / CashN/A175.8435.2935.09Price / Book0.124.044.914.96Net Income-$12.30M-$41.68M$117.36M$224.10M7 Day Performance-11.16%6.57%2.75%2.01%1 Month Performance-22.38%5.81%1.71%9.79%1 Year Performance-76.31%38.20%36.01%29.97% Palisade Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PALIPalisade Bio2.4393 of 5 stars$2.15-10.4%$23.00+969.8%-73.6%$2.86M$250,000.00-0.1510Gap DownTLPHTalphera3.743 of 5 stars$0.76+7.4%$4.50+492.9%N/A$12.93M$650,000.00-1.0319Positive NewsWENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpIMNNImunon2.7082 of 5 stars$0.86+2.1%$20.50+2,282.6%-8.4%$12.48M$500,000.00-0.4633Gap UpCDIOCardio Diagnostics3.4225 of 5 stars$0.31+1.3%$2.00+549.4%-80.7%$12.46M$20,000.000.007Gap UpNLSPNLS Pharmaceutics0.695 of 5 stars$3.18-5.9%N/A+396.7%$12.13MN/A0.006TSBXTurnstone Biologics2.6903 of 5 stars$0.51-1.4%$2.13+315.5%-73.9%$11.83M$19.31M-0.1582JAGXJaguar Health0.2254 of 5 stars$1.00-3.8%N/A-95.2%$11.80M$9.76M0.0050Short Interest ↑ENSCEnsysce Biosciences0.3919 of 5 stars$0.59+19.4%N/A-35.2%$11.54M$2.23M-0.2710Gap UpATHEAlterity Therapeutics2.8502 of 5 stars$1.49+5.7%$4.00+168.5%-8.4%$10.88MN/A0.0010Positive NewsHigh Trading VolumeIPAImmunoPrecise Antibodies3.1136 of 5 stars$0.37-2.5%$6.00+1,519.4%-77.9%$10.68M$24.09M-0.4780Positive News Related Companies and Tools Related Companies TLPH Alternatives WENA Alternatives IMNN Alternatives CDIO Alternatives NLSP Alternatives TSBX Alternatives JAGX Alternatives ENSC Alternatives ATHE Alternatives IPA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PALI) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
